168 related articles for article (PubMed ID: 31589249)
1. Miscategorization of Deaths in the US Food and Drug Administration Adverse Events Database.
Meier L; Wang EY; Tomes M; Redberg RF
JAMA Intern Med; 2020 Jan; 180(1):147-148. PubMed ID: 31589249
[TBL] [Abstract][Full Text] [Related]
2. The Weber effect and the United States Food and Drug Administration's Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010.
Hoffman KB; Dimbil M; Erdman CB; Tatonetti NP; Overstreet BM
Drug Saf; 2014 Apr; 37(4):283-94. PubMed ID: 24643967
[TBL] [Abstract][Full Text] [Related]
3. Drug makers' adverse event reports are often incomplete, US report finds.
McCarthy M
BMJ; 2015 Feb; 350():h651. PubMed ID: 25652561
[No Abstract] [Full Text] [Related]
4. Adverse drug events and near misses: who's counting?
Wu AW
Am J Med; 2000 Aug; 109(2):166-8. PubMed ID: 10967161
[No Abstract] [Full Text] [Related]
5. Food and Drug Administration Adverse Event Reports of Retinal Vascular Occlusions Associated With Phosphodiesterase Type 5 Inhibitor Use.
Li AS; Pomeranz HD
J Neuroophthalmol; 2016 Dec; 36(4):480-481. PubMed ID: 27851718
[No Abstract] [Full Text] [Related]
6. Malignancies and ustekinumab: an analysis of the U.S. Food and Drug Administration Adverse Event Reporting System and the European Union Drug Regulating Authorities Pharmacovigilance database.
Florek AG; Nardone B; Thareja S; Tran G; Giles FJ; West DP
Br J Dermatol; 2017 Nov; 177(5):e220-e221. PubMed ID: 28646575
[No Abstract] [Full Text] [Related]
7. The role of databases in drug postmarketing surveillance.
Rodriguez EM; Staffa JA; Graham DJ
Pharmacoepidemiol Drug Saf; 2001; 10(5):407-10. PubMed ID: 11802586
[TBL] [Abstract][Full Text] [Related]
8. Reporting of Death in US Food and Drug Administration Medical Device Adverse Event Reports in Categories Other Than Death.
Lalani C; Kunwar EM; Kinard M; Dhruva SS; Redberg RF
JAMA Intern Med; 2021 Sep; 181(9):1217-1223. PubMed ID: 34309624
[TBL] [Abstract][Full Text] [Related]
9. Can Disproportionality Analysis of Post-marketing Case Reports be Used for Comparison of Drug Safety Profiles?
Michel C; Scosyrev E; Petrin M; Schmouder R
Clin Drug Investig; 2017 May; 37(5):415-422. PubMed ID: 28224371
[TBL] [Abstract][Full Text] [Related]
10. Exploring the FDA adverse event reporting system to generate hypotheses for monitoring of disease characteristics.
Fang H; Su Z; Wang Y; Miller A; Liu Z; Howard PC; Tong W; Lin SM
Clin Pharmacol Ther; 2014 May; 95(5):496-8. PubMed ID: 24448476
[TBL] [Abstract][Full Text] [Related]
11. FDA turns to electronic "sentinel" to flag prescription drug safety problems.
Kuehn BM
JAMA; 2008 Jul; 300(2):156-7. PubMed ID: 18612108
[No Abstract] [Full Text] [Related]
12. Worldwide reporting of fatal outcomes after ticagrelor to the US Food and Drug Administration.
Serebruany VL; Kim MH; Marciniak TA
Eur Heart J Cardiovasc Pharmacother; 2018 Jan; 4(1):6-9. PubMed ID: 29240872
[No Abstract] [Full Text] [Related]
13. Postmarketing safety surveillance of trivalent recombinant influenza vaccine: Reports to the Vaccine Adverse Event Reporting System.
Woo EJ; Moro PL; Cano M; Jankosky C
Vaccine; 2017 Oct; 35(42):5618-5621. PubMed ID: 28886946
[TBL] [Abstract][Full Text] [Related]
14. Illusions of objectivity and a recommendation for reporting data mining results.
Hauben M; Reich L; Gerrits CM; Younus M
Eur J Clin Pharmacol; 2007 May; 63(5):517-21. PubMed ID: 17364192
[TBL] [Abstract][Full Text] [Related]
15. Outliers and patients with adverse drug reactions.
Edwards IR
Drug Saf; 2009; 32(8):623-4. PubMed ID: 19591527
[No Abstract] [Full Text] [Related]
16. Novel Adverse Events of Iloperidone: A Disproportionality Analysis in US Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
Subeesh V; Maheswari E; Singh H; Beulah TE; Swaroop AM
Curr Drug Saf; 2019; 14(1):21-26. PubMed ID: 30362421
[TBL] [Abstract][Full Text] [Related]
17. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
Welch HK; Kellum JA; Kane-Gill SL
Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524
[TBL] [Abstract][Full Text] [Related]
18. US Food and Drug Administration: adverse event reporting.
Graham AA
CRNA; 1998 Nov; 9(4):135-8. PubMed ID: 9866488
[TBL] [Abstract][Full Text] [Related]
19. Signal selection and follow-up in pharmacovigilance.
Meyboom RH; Lindquist M; Egberts AC; Edwards IR
Drug Saf; 2002; 25(6):459-65. PubMed ID: 12071784
[TBL] [Abstract][Full Text] [Related]
20. Adverse drug and device reactions in the oral cavity: surveillance and reporting.
Zavras AI; Rosenberg GE; Danielson JD; Cartsos VM
J Am Dent Assoc; 2013 Sep; 144(9):1014-21. PubMed ID: 23989840
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
